8-K current report · filed Aug 5, 2026

Sight Sciences, Inc. (SGHT) 8-K Current Report: August 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2SGHT overview

Short answer

Sight Sciences, Inc. (SGHT) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q2 2026 results announced for quarter ended June 30, 2026.

Sight Sciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • 2026 revenue guidance raised, signaling stronger expected sales performance
  • Adjusted operating expense guidance reduced, indicating improved cost expectations
  • Full financial details and updated outlook in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Investor presentation posted August 5, 2026 under Regulation FD
  • Exhibit 99.2 contains materials management expects to use with investors and analysts
  • Presentation may be modified, making website materials relevant for updated company messaging

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $23.4M, up 20% YoY; glaucoma revenue rose 8% while dry-eye revenue surged 704% to $2.7M
  • Gross margin reached 91.4%, with dry-eye margin improving to 84.7% from 38.4% YoY
  • Net loss narrowed to $4.4M, or $0.08 per share, from $11.9M and $0.23 per share
  • Full-year revenue guidance raised to $88M–$92M; adjusted operating expense guidance reduced to $92M–$94M
  • Reimbursement expansion added 4.1M dry-eye lives and 25M glaucoma lives through Aetna coverage; OMNI Ultra received FDA 510(k) clearance

Item EX-99.2 · Exhibit EX-99.2

  • FY2026 revenue guidance: $88M-$92M, implying return to double-digit growth and approximately 13% CAGR from FY2021
  • Q2 2026 revenue growth: 20% year over year, supporting the company’s projected growth recovery
  • Adjusted operating expense guidance: $92M-$94M, indicating continued substantial investment in commercial infrastructure
  • TearCare opportunity: $2.4B U.S. dry-eye treatment market and approximately 19 million diagnosed patients
  • OMNI installed base: over 400,000 procedures, targeting a $5B standalone and combination MIGS opportunity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Sight Sciences, Inc. 8-K filings

Get the next SGHT 8-K as it lands

Follow SGHT for push alerts, or ask the research agent what this filing means.